Hematology/Oncology

Top Story

Ovarian cancer surveillance with CA-125 tests, CT scans common despite lack of proven benefit

July 29, 2016

Cancer antigen 125 tests and CT scans are routinely used for surveillance of patients with ovarian cancer despite a lack of proven benefit, according to results of a prospective cohort study.

Cancer antigen 125 (CA-125) testing for routine surveillance in ovarian cancer failed to extend survival, increased chemotherapy use and decreased patients’ quality of life compared with clinical observation, according to results of a randomized clinical trial presented by Rustin and colleagues at the ASCO Annual Meeting in 2009.

In the Journals Plus

High-dose methotrexate improves outcomes in children with B-ALL

July 29, 2016
High-dose methotrexate appeared superior to Capizzi methotrexate without increasing toxicity in children and young adults with high-risk B-acute lymphoblastic leukemia…
In the Journals Plus

Melanoma screening increases detection with little impact on use of surgery, specialist referrals

July 28, 2016
Melanoma screening in the community medical setting increased melanoma diagnoses rates, but did not result in an upsurge of skin surgeries or dermatology office visits…
At Issue

Checkpoint inhibitor therapy more economical, safe than CAR T cells in pediatric leukemia

July 28, 2016
Novel advances in the use of checkpoint inhibitors – such as an anti-PD1 or anti-PDL1 – to treat pediatric leukemia may result in the ability to eliminate…
In the Journals Plus

Tasquinimod prolongs radiographic PFS, not OS, in metastatic prostate cancer

July 28, 2016
Tasquinimod significantly improved radiographic PFS in men with chemotherapy-naive, metastatic castration-resistant prostate cancer, according to the results of a…
More News Headlines »
CME

Management of Multiple Myeloma: Using Emerging Therapies with ASCT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Spectrum Pharmaceuticals, Inc.; and Takeda Oncology.

Multiple myeloma management has undergone profound changes in the past few decades, this is largely due to advances in…
More »
Video
Meeting News Coverage

VIDEO: CPX-351 demonstrates survival advantage in patients with secondary AML

July 21, 2016
More »
Featured
2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

CME

The Patient with Myelofibrosis

No commercial support for this activity.

Myelofibrosis is caused by abnormal stem cells in the bone marrow that cause the uncontrolled production of mature…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan